BNT114 + BNT121

**BNT114 + BNT121** is an investigational combination of two mRNA-based cancer vaccines developed by BioNTech. **BNT114** is a FixVac-platform vaccine encoding a fixed set of breast cancer-associated tumor-associated antigens (TAAs), while **BNT121** encodes up to 10 patient-specific neoantigens, delivered via intranodal administration to stimulate T-cell responses against tumor cells. This combination aims to enhance antitumor immunity by targeting both shared and individualized tumor antigens, primarily for advanced solid tumors including breast cancer and melanoma, leveraging BioNTech's uridine mRNA technology for optimized immunogenicity and safety.